Finasteride Tablet, Film Coated
Product Images NDC 43598-303

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 43598-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr Reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container (Container)

Packaging label for Finasteride 5 mg film-coated tablets by Dr Reddys Laboratories Inc. The label indicates 90 oral tablets per package with storage instructions and warnings. The design features a red and blue color scheme and a barcode. It is marked for prescription use only.*

FDA Label Image

Figure1 (Figure1)

A line graph comparing the mean change from baseline over four years between Finasteride and placebo groups. The graph plots data points from baseline to year 4 on the x-axis, with mean change values on the y-axis. Finasteride shows a greater decrease from baseline compared to placebo throughout the study period.*

FDA Label Image

Figure2 (Figure2)

A line graph comparing the percent of patients undergoing surgery for BPH, including TURP, over 48 months between Finasteride and placebo groups. The graph shows cumulative event counts and patient risk numbers for each group at different observation times.*

FDA Label Image

Figure3 (Figure3)

A line graph showing the mean percent change from baseline with standard error over a four-year period for two groups: placebo and finasteride. The vertical axis represents percent change, ranging from -20 to 20, and the horizontal axis shows time points from baseline through year 4. Two lines depict trends, with finasteride showing a downward trend and placebo an upward trend.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting the percentage of patients with an event over approximately 5.5 years from randomization. It compares four groups: Placebo, Finasteride, Doxazosin, and a Combination treatment, showing event rates increasing over time with variations between the groups.*

FDA Label Image

Structure (Structure)

Chemical structure of Finasteride depicted in a standard skeletal formula showing its molecular framework and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.